AI cuts surgical waste; tariffs upheld again
Supply Chain Pulse — 2026-06-16
A federal appeals court moved Friday to temporarily reinstate Trump's 10% global tariff while legal challenges play out — keeping cost pressure squarely on hospital supply chains that import devices, consumables, and raw materials. Against that backdrop, health systems aren't waiting: Mayo Clinic, Mount Sinai, and others are deploying AI to wring waste out of surgical supply spending, one of the last major cost levers still within a supply chain leader's direct control. Meanwhile, Danaher's finalized acquisition of Masimo reshapes the monitoring device landscape just as you're likely mid-cycle on your next contract review. The throughline today is control — who has it, who's building it, and who's ceding it.
Providers Are Leaning Into AI to Control Surgical Supply Spending
Health systems including Mayo Clinic and Mount Sinai are deploying AI tools to reduce waste and cut costs in the OR, one of the highest-spend, lowest-visibility environments in any hospital. Surgical supplies can account for 40–60% of a health system's total supply spend, making even marginal efficiency gains material to the bottom line. If you're not piloting something in this space yet, your peers already are — and the gap will show up in your next board presentation.
Federal Court Temporarily Upholds Trump's 10% Global Tariff
A federal appeals court blocked a lower court's order that had halted collection of the 10% blanket tariff for two importers and the state of Washington, keeping the duties in effect while the appeal proceeds. For healthcare supply chain teams sourcing internationally — think medical devices, PPE, and raw materials — this signals the tariff environment remains volatile and litigation-dependent, not resolved. Now is a good time to revisit your import exposure and confirm your cost-impact modeling reflects the tariff staying in place through at least year-end.
Danaher Finalizes Masimo Acquisition, CEO Steps Down
Danaher completed its acquisition of Masimo, making the patient monitoring company a wholly owned subsidiary and prompting the departure of CEO Katie Szyman. For supply chain and value analysis teams, a change in corporate ownership of a major monitoring device supplier typically signals potential product portfolio shifts, pricing renegotiations, and GPO contract realignments ahead. Flag this for your next Masimo contract review and watch for any bundling plays as Danaher integrates the asset.
J&J Commits $1B to Florida Contact Lens Manufacturing
Johnson & Johnson announced a $1 billion investment to expand domestic production of its ACUVUE contact lenses at its Florida facility, explicitly framing the move as a supply chain resilience play. While contact lenses sit outside most acute-care supply chains, the broader signal matters: major device manufacturers are accelerating domestic manufacturing investments in response to tariff risk and global supply volatility. Expect this trend to influence supplier pricing conversations and lead-time commitments across categories as companies recoup onshoring costs.
Source: Medical Device Network
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe